Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 1:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 418 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Thyroid Gland Carcinoma Clear all
Recruiting No phase listed Observational

Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

NCT01005654
View directory record Official record
Conditions
Endocrine Tumors, Thyroid Neoplasms, Parathyroid Neoplasms, Adrenal Neoplasm, Neuroblastoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Years and older
Enrollment
2,415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 1 Interventional

Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma

NCT00413075
View directory record Official record
Conditions
Solid Tumor, Lymphoma
Interventions
oral belinostat
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
4
States / cities
New Haven, Connecticut • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 6, 2026, 1:09 PM EDT
Enrolling by invitation No phase listed Observational

Pressure-enabled Retrograde Occlusive Therapy With Embolization for Control of Thyroid Disease (PROTECT Registry): A Multicenter Registry

NCT06868459
View directory record Official record
Conditions
Hyperthyroidism; Goiter, Multinodular Goiter, Thyroid Nodules, Thyroid Disease, Hyperthyroidism, Toxic Multinodular Goiter
Interventions
Data Collection
Other
Lead sponsor
Sarasota Memorial Health Care System
Other
Eligibility
18 Years to 89 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Jacksonville, Florida • Sarasota, Florida • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 6, 2026, 1:09 PM EDT
Active, not recruiting Phase 1 Interventional

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

NCT03170960
View directory record Official record
Conditions
Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer
Interventions
cabozantinib, atezolizumab
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
914 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
57
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 6, 2026, 1:09 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

NCT05557045
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Solid Tumor, Melanoma, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Anaplastic Thyroid Cancer (ATC)
Interventions
JZP815
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Denver, Colorado • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 6, 2026, 1:09 PM EDT
Terminated Phase 2 Interventional Results available

Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer

NCT02408887
View directory record Official record
Conditions
Low-risk Papillary Thyroid Cancer, Endocrine Malignancy, Thyroid Cancer
Interventions
Total Thyroidectomy (TT), Prophylactic central neck lymph node dissection (pCND)
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 2 Interventional Results available

Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer

NCT02138214
View directory record Official record
Conditions
Stage I Papillary Thyroid Cancer, Stage II Papillary Thyroid Cancer, Stage III Papillary Thyroid Cancer
Interventions
Thyroidectomy, entral lymph node dissection (CLND), Quality-of-life assessment
Procedure · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 73 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 6, 2026, 1:09 PM EDT
Active, not recruiting Phase 2 Interventional

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

NCT03449108
View directory record Official record
Conditions
Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone, Malignancy in Giant Cell Tumor of Bone, Malignant Solid Neoplasm, Ovarian Carcinosarcoma, Platinum-Resistant Ovarian Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Osteosarcoma, Recurrent Ovarian Carcinoma, Refractory Osteosarcoma, Soft Tissue Sarcoma, Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell Carcinoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone, Triple Negative Breast Cancer
Interventions
Aldesleukin, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1, Cyclophosphamide, Fludarabine, Ipilimumab, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
Biological · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 4 Interventional

Minimizing Narcotic Analgesics After Endocrine Surgery

NCT03469310
View directory record Official record
Conditions
Thyroid Cancer, Thyroid Nodule, Thyroid Neoplasms, Thyroid Goitre, Thyroid Diseases, Parathyroid Diseases, Parathyroid Adenoma, Parathyroid Hyperplasia
Interventions
Acetaminophen 500Mg Cap, Tylenol #3 Oral Tablet, Tramadol
Drug
Lead sponsor
Minerva A Romero Arenas
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Edinburg, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Spectroscopy With Surface Coils and Decoupling

NCT00581815
View directory record Official record
Conditions
Adrenal Cortical Cancer, Brain Cancer, Breast Cancer, CNS Cancer, Colon Cancer, HEENT Cancer, Hodgkin's Disease, Kaposi's Sarcoma, Liver Cancer, Lung Cancer, Non-Hodgkin's Lymphoma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cancer, Sarcoma, Squamous Cell Carcinoma, Thyroid Cancer
Interventions
Proton-decoupled 31P MRS at 1.5T, 1H Spectroscopy at 1.5T and 3T
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
582 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2015 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 2 Interventional

Molecular Testing to Direct Extent of Initial Thyroid Surgery

NCT02947035
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Thyroid lobectomy, Total thyroidectomy with CCND
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 6, 2026, 1:09 PM EDT
Completed No phase listed Observational

An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors

NCT02303444
View directory record Official record
Conditions
Thyroid Neoplasms
Interventions
Sorafenib (Nexavar, BAY43-9006), Other Multikinase inhibitors
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Torrance, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 6, 2026, 1:09 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Study of Multiparametric Ultrasound Imaging Methods

NCT07270237
View directory record Official record
Conditions
Pancreatic Cancer, Thyroid Nodule
Interventions
Multiparametric ultrasound (mpUS) imaging
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 2 Interventional Results available

Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology

NCT00784303
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Lenvatinib (DTC Cohort), Lenvatinib (MTC Cohort)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
23
States / cities
Little Rock, Arkansas • Los Angeles, California • Los Gatos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Oct 6, 2026, 1:09 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Role of NGS-based ThyroSeq Panel in Cancer Diagnosis in Thyroid Nodules

NCT02352766
View directory record Official record
Conditions
Thyroid Nodule
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Oct 6, 2026, 1:09 PM EDT
Completed No phase listed Observational

Thyroid Ultrasound Elasticity (TrUE) Imaging

NCT03307694
View directory record Official record
Conditions
Cancer, Thyroid
Interventions
Ultrasound, Shear wave elasticity imaging, Multi-angle compound shear wave elasticity imaging
Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 6, 2026, 1:09 PM EDT
Terminated Phase 2 Interventional

Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors

NCT00466856
View directory record Official record
Conditions
Head and Neck Cancer, Islet Cell Tumor, Metastatic Cancer, Pheochromocytoma
Interventions
octreotide acetate, yttrium Y 90 resin microspheres
Drug · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 18, 2012 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Not applicable Interventional Results available

Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244

NCT00970359
View directory record Official record
Conditions
Thyroid Cancer
Interventions
AZD6244
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 6, 2026, 1:09 PM EDT
Terminated Phase 1 Interventional Results available

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

NCT04234113
View directory record Official record
Conditions
Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Melanoma, Merkel Cell Carcinoma, Skin Squamous Cell Carcinoma, Microsatellite Instability High, Triple Negative Breast Cancer, Mesothelioma, Thymic Cancer, Cervical Cancer, Biliary Tract Cancer, Hepatocellular Carcinoma, Ovarian Cancer, Gastric Cancer, Head and Neck Squamous Cell Carcinoma, Anal Cancer
Interventions
Nanrilkefusp alfa, Pembrolizumab
Drug
Lead sponsor
SOTIO Biotech AG
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
New Haven, Connecticut • Pittsburgh, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 2 Interventional Results available

Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine

NCT00559949
View directory record Official record
Conditions
Recurrent Thyroid Gland Carcinoma, Stage I Thyroid Gland Papillary Carcinoma, Stage II Thyroid Gland Papillary Carcinoma, Stage III Thyroid Gland Papillary Carcinoma, Stage IV Thyroid Gland Papillary Carcinoma
Interventions
Laboratory Biomarker Analysis, Selumetinib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
5
States / cities
Tampa, Florida • Chicago, Illinois • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 6, 2026, 1:09 PM EDT
Recruiting Phase 2 Interventional

The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer

NCT04927416
View directory record Official record
Conditions
Metastic Thyroid Cancer
Interventions
68-Gallium-DOTATATE-PET/CT
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 98 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 6, 2026, 1:09 PM EDT
Recruiting No phase listed Observational

Cultural Adaptation of an Educational Tool in Medullary Thyroid Cancer

NCT07142005
View directory record Official record
Conditions
Medullary Thyroid Cancer (MTC), Cultural Adaptation
Interventions
Interviews
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 6, 2026, 1:09 PM EDT
Recruiting Not applicable Interventional

Personalized Treatment in Thyroid Disorders

NCT03517579
View directory record Official record
Conditions
Thyroid Cancer, Graves Disease
Interventions
Cervical Collar Therapy Indicator (COTI)
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 6, 2026, 1:09 PM EDT
Recruiting Phase 1 Interventional

Brodalumab in the Treatment of Immune-Related Adverse Events

NCT06673329
View directory record Official record
Conditions
Breast Cancer, Esophageal Cancer, Kidney Cancer, Lung Cancer, Thyroid Cancer, Gynecologic Cancer, Pancreatic Cancer, Stomach Cancer, Brain Tumor, Colon Cancer, Rectal Cancer, Head and Neck Cancer, Oral Cancer, Liver Cancer, Skin Cancer, Prostate Cancer, Testicular Cancer, Solid Tumor
Interventions
Brodalumab, CT scan
Drug · Radiation
Lead sponsor
Brian Henick, MD
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 6, 2026, 1:09 PM EDT